Actinium to send personnel to BMT Tandem Meetings

Actinium Pharmaceuticals announced this week that it will be sending personnel from clinical and business development to the annual BMT Tandem Meetings held by the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT).

Actinium is a biopharmaceutical company that develops immunotherapeutics for cancer treatment.

Actinium has numerous market and clinical development activities planned for the BMT Tandem Meetings, which will be held on February 18-22 at the Hawaii Convention Center in Honolulu, Hawaii. The meetings are the largest gathering involving the transplant community and is known to spur clinical trials. There will be an effort at the upcoming BMTs to recruit for the forthcoming Iomab-B trial.

It is an event that Actinium will use to network and market so it can increase its outreach. During the meetings, the Scientific Advisory Board will feature the Iomab-B trial during a presentation. The upcoming trial is very important for the success of the drug. Iomab-B is a therapy designed for patients who have relapsed and refractory Acute Myeloid Leukemia to condition them before a bone marrow transplant.